- Home
- TRBG vs BSEM Comparison
TRBG vs BSEM Comparison
Compare TRBG & BSEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRBG | BSEM |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | Israel | United States |
| Employees | 20 | N/A |
| Industry | Power Generation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.2M | 76.9M |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | TRBG | BSEM |
|---|---|---|
| Price | $3.51 | $1.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 48.6K | ★ 141.5K |
| Earning Date | 09-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $87.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.13 | $1.45 |
| 52 Week High | $5.84 | $5.44 |
Technical Indicators
Market Signals| Indicator | TRBG | BSEM |
|---|---|---|
| Relative Strength Index (RSI) | 37.00 | 28.12 |
| Support Level | $3.50 | $1.45 |
| Resistance Level | $3.78 | $4.02 |
| Average True Range (ATR) | 0.23 | 0.28 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 43.93 | 17.43 |
Price Performance
Historical ComparisonAbout TRBG TurboGen Ltd. Ordinary Shares
Turbogen Ltd is engaged in developing multifuel CHP systems with a vision of providing on-site energy for buildings. Its CHP systems outperform current electric efficiency solutions, enabling fast ROI, lower building emissions, and peak saving for utilities. The company's multi-fuel technology enables hybrid Operations: Solar-Gas, Hydrogen-Gas, SOFC-Gas.
About BSEM BioStem Technologies Inc. Common Stock
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.